TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma

Erling Håland, Ingrid Nyhus Moen, Esten N. Vandsemb & Kristian K. Starheim
Abstract Objective Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TAK1) has recently gained attention as a potential drug target in multiple myeloma. This study aimed at determining the in vivo effects of TAK1-inhibitors in a Vκ*MYC multiple myeloma mouse model. Results We treated mice...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.